www.TheFinancialMarketingGroup.com
Followers | 59 |
Posts | 2,197 |
Boards Moderated | 4 |
Alias Born | 04/28/2019 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ENSV - Increasing Volume + Media Presence. Resistance Test Due!
Enservco Corporation provides well and fluid management services to the domestic onshore oil and natural gas industry. The Company's services include frac water heating, hot oiling and acidizing (well enhancement services), and water transfer, water treatment, water hauling, fluid disposal, frac tank rental (fluid management services) and other general oilfield services. Well enhancement services consist of frac water heating, acidizing, hot oiling services and pressure testing. These services are provided by its subsidiary, Heat Waves Hot Oil Service LLC (Heat Waves), which utilize a fleet of approximately 200 custom designed trucks and other related equipment. The Company owns or leases, and operates approximately 65 water-hauling trucks and trailers equipped with pumps to move water from or into wells, tanks and other storage facilities. Each truck has a hauling capacity of approximately 130 barrels. It also provides well-site construction and roustabout services.
SHORT INTEREST
464.49K 07/15/19
P/E Current
-4.11
P/E Ratio (with extraordinary items)
-6.99
Average Recommendation: BUY
Average Target Price: 1.33
FOMX - Bulls Arrive As Big Investment Happens
Foamix Pharmaceuticals Ltd . is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.
Foamix Pharmaceuticals Ltd . ( FOMX ), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it has secured up to $64 million in financing from Perceptive Advisors and OrbiMed. The financing consists of term loans of up to $50 million under a Credit Agreement, with $15 million provided immediately upon satisfaction of certain closing conditions, $20 million available upon the achievement of certain regulatory milestones and $15 million available upon the achievement of certain revenue milestones. Additionally, the Company will receive $14 million in gross proceeds from Perceptive Advisors through a direct registered offering of the Company’s ordinary shares. Proceeds from the transactions are expected to be used to fund the Company’s filing of a New Drug Application (“NDA”) with the FDA for FMX103 for the treatment of papulopustular rosacea as well as, assuming FDA approval is received, the anticipated product launches of FMX101 for the treatment of moderate to severe acne and FMX103, as well as for working capital and general corporate purposes. The FDA has established October 20th, 2019 as the Prescription Drug User Fee Act (PDUFA) action date for FMX101, and Foamix is in the final stages of preparation for the NDA submission for FMX103. (Source https://finance.yahoo.com/news/foamix-an...)
SHORT INTEREST
2.11M 07/15/19
Average Recommendation: BUY
Average Target Price: 15.60
P/E Current
-1.26
P/E Ratio (with extraordinary items)
-1.84
FOMX - Bulls Arrive As Big Investment Happens
Foamix Pharmaceuticals Ltd . is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.
Foamix Pharmaceuticals Ltd . ( FOMX ), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it has secured up to $64 million in financing from Perceptive Advisors and OrbiMed. The financing consists of term loans of up to $50 million under a Credit Agreement, with $15 million provided immediately upon satisfaction of certain closing conditions, $20 million available upon the achievement of certain regulatory milestones and $15 million available upon the achievement of certain revenue milestones. Additionally, the Company will receive $14 million in gross proceeds from Perceptive Advisors through a direct registered offering of the Company’s ordinary shares. Proceeds from the transactions are expected to be used to fund the Company’s filing of a New Drug Application (“NDA”) with the FDA for FMX103 for the treatment of papulopustular rosacea as well as, assuming FDA approval is received, the anticipated product launches of FMX101 for the treatment of moderate to severe acne and FMX103, as well as for working capital and general corporate purposes. The FDA has established October 20th, 2019 as the Prescription Drug User Fee Act (PDUFA) action date for FMX101, and Foamix is in the final stages of preparation for the NDA submission for FMX103. (Source https://finance.yahoo.com/news/foamix-an...)
SHORT INTEREST
2.11M 07/15/19
Average Recommendation: BUY
Average Target Price: 15.60
P/E Current
-1.26
P/E Ratio (with extraordinary items)
-1.84
ROX - Trend Reversal - HOW HIGH CAN IT GO?
Castle Brands Inc . develops and markets premium and super premium brands in the beverage alcohol categories. The Company is engaged in the sale of premium beverage alcohol. Its beverage alcohol categories include rum, whiskey, liqueurs, vodka and tequila. Its brands include Gosling's rum, Gosling's Stormy Ginger Beer, Gosling's Dark 'n Stormy ready-to-drink cocktail, Jefferson's bourbon, Jefferson's Reserve, Jefferson's Ocean Aged at Sea, Jefferson's Wine Finish Collection, Jefferson's The Manhattan: Barrel Finished Cocktail, Jefferson's Chef's Collaboration, Jefferson's Wood Experiment, Jefferson's Presidential Select, Jefferson's Rye whiskey, Pallini liqueurs, Clontarf Irish whiskey, Knappogue Castle Whiskey, Brady's Irish Cream, Boru vodka, Tierras tequila, Celtic Honey liqueur and Gozio amaretto. It has operations in two geographic areas: International and the United States. The Company distributes its products in all 50 states of the United States and the District of Columbia.
SHORT INTEREST
3.6M 07/15/19
Average Recommendation: OVERWEIGHT
Average Target Price: 1.35
P/E Current
16.68
P/E Ratio (with extraordinary items)
16.65
P/E Ratio (without extraordinary items)
21.23
ROX - Trend Reversal - HOW HIGH CAN IT GO?
Castle Brands Inc . develops and markets premium and super premium brands in the beverage alcohol categories. The Company is engaged in the sale of premium beverage alcohol. Its beverage alcohol categories include rum, whiskey, liqueurs, vodka and tequila. Its brands include Gosling's rum, Gosling's Stormy Ginger Beer, Gosling's Dark 'n Stormy ready-to-drink cocktail, Jefferson's bourbon, Jefferson's Reserve, Jefferson's Ocean Aged at Sea, Jefferson's Wine Finish Collection, Jefferson's The Manhattan: Barrel Finished Cocktail, Jefferson's Chef's Collaboration, Jefferson's Wood Experiment, Jefferson's Presidential Select, Jefferson's Rye whiskey, Pallini liqueurs, Clontarf Irish whiskey, Knappogue Castle Whiskey, Brady's Irish Cream, Boru vodka, Tierras tequila, Celtic Honey liqueur and Gozio amaretto. It has operations in two geographic areas: International and the United States. The Company distributes its products in all 50 states of the United States and the District of Columbia.
SHORT INTEREST
3.6M 07/15/19
Average Recommendation: OVERWEIGHT
Average Target Price: 1.35
P/E Current
16.68
P/E Ratio (with extraordinary items)
16.65
P/E Ratio (without extraordinary items)
21.23
WISA - Quarter Update In 16 Days - HIGH RISK HIGH REWARD
Summit Wireless Technologies Inc ., formerly Summit Semiconductor, Inc. is an early-stage company that develops and sells wireless audio integrated circuits for home entertainment and professional audio markets. The Company develops and provides semiconductors and wireless audio modules to consumer electronics companies, which transmits and receives audio directly to speakers. Its technologies focus on providing wireless, interference free and uncompressed high-definition audio signals. Its subsidiaries include Summit Semiconductor, Inc., Summit Semiconductor K.K., and WiSA , LLC.
Average Recommendation: BUY
Average Target Price: 4.00
P/E Current
-0.11
P/E Ratio (with extraordinary items)
-0.29
SHORT INTEREST
72.01K 07/15/19
This is a very risky trade, we recommend waiting on this one, maybe set alerts for close to the time of announcements. Clear direction in chart movement is required with tight-stops.
WISA - Quarter Update In 16 Days - HIGH RISK HIGH REWARD
Summit Wireless Technologies Inc ., formerly Summit Semiconductor, Inc. is an early-stage company that develops and sells wireless audio integrated circuits for home entertainment and professional audio markets. The Company develops and provides semiconductors and wireless audio modules to consumer electronics companies, which transmits and receives audio directly to speakers. Its technologies focus on providing wireless, interference free and uncompressed high-definition audio signals. Its subsidiaries include Summit Semiconductor, Inc., Summit Semiconductor K.K., and WiSA , LLC.
Average Recommendation: BUY
Average Target Price: 4.00
P/E Current
-0.11
P/E Ratio (with extraordinary items)
-0.29
SHORT INTEREST
72.01K 07/15/19
This is a very risky trade, we recommend waiting on this one, maybe set alerts for close to the time of announcements. Clear direction in chart movement is required with tight-stops.
AAU - ARE WE ABOUT TO START A 5TH WAVE?
Almaden Minerals Ltd. is exploration- and development-stage company and is engaged in the exploration and development of exploration and evaluation properties in Canada, the United States and Mexico. The Company is engaged in the business of the acquisition of mineral properties. Its principal property interest includes the Tuligtic Property/Project-Mexico. It has interest in ATW Resources Ltd. ( ATW ) that holds title in trust for the ATW project. It holds an interest in the Logan property located in the Yukon Territory, Canada. It has approximately two subsidiaries, including Puebla Holdings Inc., which is a holding company and Minera Gorrion, S.A. de C.V., which is an exploration company. Its Ixtaca deposit, the epithermal gold-silver target within the Tuligtic Property, is located approximately eight kilometers northwest of the town of San Francisco Ixtacamaxtitlan. The Company has not generated any revenues from its operations.
SHORT INTEREST
1.63M 07/15/19
P/E Current
-30.94
P/E Ratio (with extraordinary items)
-31.55
Average Recommendation: HOLD
Average Target Price: 1.10
AAU - ARE WE ABOUT TO START A 5TH WAVE?
Almaden Minerals Ltd. is exploration- and development-stage company and is engaged in the exploration and development of exploration and evaluation properties in Canada, the United States and Mexico. The Company is engaged in the business of the acquisition of mineral properties. Its principal property interest includes the Tuligtic Property/Project-Mexico. It has interest in ATW Resources Ltd. ( ATW ) that holds title in trust for the ATW project. It holds an interest in the Logan property located in the Yukon Territory, Canada. It has approximately two subsidiaries, including Puebla Holdings Inc., which is a holding company and Minera Gorrion, S.A. de C.V., which is an exploration company. Its Ixtaca deposit, the epithermal gold-silver target within the Tuligtic Property, is located approximately eight kilometers northwest of the town of San Francisco Ixtacamaxtitlan. The Company has not generated any revenues from its operations.
SHORT INTEREST
1.63M 07/15/19
P/E Current
-30.94
P/E Ratio (with extraordinary items)
-31.55
Average Recommendation: HOLD
Average Target Price: 1.10
RISKY MOVE BDR PUSH DUE TO NEWS ANNOUNCEMENT
Blonder Tongue Laboratories, Inc. (Blonder Tongue), along with its subsidiary, R. L. Drake Holdings, LLC (RLD), is a technology-development and manufacturing company. The Company delivers a range of products and services to the cable entertainment and media industry. Its products are deployed in a list of locations, including lodging/hospitality, multi-dwelling units/apartments, broadcast studios/networks, universities/schools, healthcare/hospitals and airports. Blonder Tongue's products are divided into three categories: Digital Video Headend, Analog Video Headend and Hybrid-Fiber Coax ( HFC ) Distribution. The Digital Video Headend products (including encoders) are used by a system operator for acquisition, processing, compression, encoding and management of digital video. The Analog Video Headend products are used by a system operator for signal acquisition, processing and manipulation. The HFC Distribution products are used to transport signals from the headend to their destination.
SHORT INTEREST
1.55K 07/15/19
P/E Current
-6.05
P/E Ratio (with extraordinary items)
2.26
News:
Blonder Tongue Laboratories Inc. (NYSE American: BDR ) is excited to announce the release of its new NXG CryptoLinktm for MobiTV. The NXG CryptoLinktm for MobiTV allows Cable, Fiber Optic and Telco Operators using the MobiTV video delivery platform a way to support B-B and Hospitality video services directly from their local IPTV distribution networks.
https://finance.yahoo.com/news/blonder-t...
RISKY MOVE BDR PUSH DUE TO NEWS ANNOUNCEMENT
Blonder Tongue Laboratories, Inc. (Blonder Tongue), along with its subsidiary, R. L. Drake Holdings, LLC (RLD), is a technology-development and manufacturing company. The Company delivers a range of products and services to the cable entertainment and media industry. Its products are deployed in a list of locations, including lodging/hospitality, multi-dwelling units/apartments, broadcast studios/networks, universities/schools, healthcare/hospitals and airports. Blonder Tongue's products are divided into three categories: Digital Video Headend, Analog Video Headend and Hybrid-Fiber Coax ( HFC ) Distribution. The Digital Video Headend products (including encoders) are used by a system operator for acquisition, processing, compression, encoding and management of digital video. The Analog Video Headend products are used by a system operator for signal acquisition, processing and manipulation. The HFC Distribution products are used to transport signals from the headend to their destination.
SHORT INTEREST
1.55K 07/15/19
P/E Current
-6.05
P/E Ratio (with extraordinary items)
2.26
News:
Blonder Tongue Laboratories Inc. (NYSE American: BDR ) is excited to announce the release of its new NXG CryptoLinktm for MobiTV. The NXG CryptoLinktm for MobiTV allows Cable, Fiber Optic and Telco Operators using the MobiTV video delivery platform a way to support B-B and Hospitality video services directly from their local IPTV distribution networks.
https://finance.yahoo.com/news/blonder-t...
ACRX - Perfect Trend Bounce 0.168 Levels On Daily
AcelRx Pharmaceuticals , Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.
SHORT INTEREST
15.09M 07/15/19
Average Recommendation: BUY
Average Target Price: 7.71
P/E Current
-3.02
P/E Ratio (with extraordinary items)
-3.90
ACRX - Perfect Trend Bounce 0.168 Levels On Daily
AcelRx Pharmaceuticals , Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office. It also includes ARX-02, which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.
SHORT INTEREST
15.09M 07/15/19
Average Recommendation: BUY
Average Target Price: 7.71
P/E Current
-3.02
P/E Ratio (with extraordinary items)
-3.90
Possible Fireworks For PIXELWORKS 3 Days Until Earnings
Pixelworks , Inc. designs, develops and markets video and pixel processing semiconductors, intellectual property cores, software and custom application specific integrated circuit ( ASIC ) solutions for digital video applications. The Company is engaged in the design and development of integrated circuits (ICs) for use in electronic display devices. It provides its customers with software development tools and with software that provides basic functionality for its ICs and enables connectivity of its customers' products. Its primary target markets include digital projection systems, Ultrabook devices, tablets and smartphones. Its video display processing technologies include Halo Free Motion Estimation and Motion Compensation (MEMC), Advanced Scaling, Mobile Video Display Processing, and Vuemagic and Networked Displays. Its primary video display processor product categories include ImageProcessor ICs, Video Co-Processor ICs and Transcoder ICs.
Pixelworks , Inc. ( PXLW ), a leading provider of advanced visual processing solutions, has received the prestigious Hollywood Professional Association (HPA) Engineering Excellence Award for its recently launched TrueCut® Motion Grading software tool suite, a key element in the TrueCut Video Platform announced earlier this year.
SHORT INTEREST
511.34K 07/15/19
P/E Current
-22.72
P/E Ratio (with extraordinary items)
-26.84
Average Recommendation: BUY
Average Target Price: 5.70
Possible Fireworks For PIXELWORKS 3 Days Until Earnings
Pixelworks , Inc. designs, develops and markets video and pixel processing semiconductors, intellectual property cores, software and custom application specific integrated circuit ( ASIC ) solutions for digital video applications. The Company is engaged in the design and development of integrated circuits (ICs) for use in electronic display devices. It provides its customers with software development tools and with software that provides basic functionality for its ICs and enables connectivity of its customers' products. Its primary target markets include digital projection systems, Ultrabook devices, tablets and smartphones. Its video display processing technologies include Halo Free Motion Estimation and Motion Compensation (MEMC), Advanced Scaling, Mobile Video Display Processing, and Vuemagic and Networked Displays. Its primary video display processor product categories include ImageProcessor ICs, Video Co-Processor ICs and Transcoder ICs.
Pixelworks , Inc. ( PXLW ), a leading provider of advanced visual processing solutions, has received the prestigious Hollywood Professional Association (HPA) Engineering Excellence Award for its recently launched TrueCut® Motion Grading software tool suite, a key element in the TrueCut Video Platform announced earlier this year.
SHORT INTEREST
511.34K 07/15/19
P/E Current
-22.72
P/E Ratio (with extraordinary items)
-26.84
Average Recommendation: BUY
Average Target Price: 5.70
HMPQ is our new & exciting sub-penny CBD alert for tomorrow.
=====================
HempAmericana, Inc (HMPQ)
Alert Price: $0.0007
Website | Recent News
========================
Members,
We are coming off and incredible week of trading.
Last Thursday's alert broke out huge on on Friday, giving our members ample time to secure up to +76% in realistic profit.
This was our 4th winning trade alert in a row.
All in all, our members have had the opportunity to secure up to +225% in realistic profit in just about two weeks time.
We plan on keeping the good times rolling with a fresh trade idea that has the potential to double in price.
Please turn your immediate attention to HempAmericana, Inc (HMPQ).
Just like our most recent winners, HMPQ is sitting on a bottom'd out chart with plenty of room to the upside.
We've had a lot of success in the cannabis sector, our last pick in this space more than doubled in price in a very short amount of time.
HMPQ is quite enticing at the moment, as there are not many companies in the CBD sector trading for less than a penny.
And if there are, it is unlikely that they own and operate a high-capacity, state-of-the-art CBD extraction and processing facility like HMPQ does.
This is an exciting time for HMPQ shareholders, as the Company is witnessing quite the growth period.
Management recently updated shareholders on current inventory levels on hand for premium-quality CBD products. As of July 15, 2019, the Company holds CBD-based product inventories in excess of $500,000 based on current market pricing for end-market sales of comparable products. This inventory represents production over the past 60 days and includes CBD Extract, Crude CBD Oil , CBD Distillate, and bottled CBD Tincture.
Management believes it will improve margins over time as production smooths out and the volume absorbs fixed operating cost.
This is the kind of news we like to hear.
Wall St . loves nothing more than healthy margins and revenue growth.
It appears that we have found another gem in the CBD space with HMPQ.
We are urging all of our members to start their research on HMPQ immediately, and consider building a position tomorrow morning at 9:30AM EST.
About HempAmericana, Inc.
HempAmericana is an emerging participant in the CBD products market. The Company owns and operates a high-capacity, state-of-the-art CBD extraction and processing facility located in Augusta, Maine. This facility is armed with a supersized supercritical CO2 extraction system, centrifugal partition chromatography refinement technology, and a mechanized fully-automated CBD bottling system. The Company’s CBD oil business uses the brand designation, “Weed Got Oil”. HempAmericana also researches, develops, and sells products made of industrial hemp, including a popular brand of hemp rolling papers marketed under the brand name, “Rolling Thunders”. See more at http://www.hempamericana.com.
This Is An Exciting Time To Be A HMPQ Shareholder
In a recent corporate update CEO Salvador Rosillo painted a picture of a company gearing up for an amazing 2nd half of 2018.
Highlights Include:
A new relationship with Eagle Hemp of Florida (“Eagle Hemp”), located in the West Palm Beach area. This relationship now comprises an initial large purchase order and a clear path for a continuing series of purchase orders set to roll out over coming months and quarters.
Vaping machine is active and fully operational, they are now ready to produce and sell CBD vapes.
Plans to build a greenhouse dedicated to cultivating super-enriched seeds.
Improved margins
Please feel free to read the entire letter to shareholders below, we think you'll be just as impressed as we are.
Dear Valued Shareholder,
As we begin to establish growing momentum in our core CBD Oil production and distribution business, I wanted to take this opportunity to express our gratitude for your commitment and loyalty to our long-term value proposition and to discuss our current opportunities and our roadmap as we gear up to execute on the powerful opportunities that lie ahead.
As you know, we have commenced bottling 500mg and 1000mg full-spectrum CBD distillate in our state-of-the-art CBD extraction and production facility in Augusta, Maine. Our inaugural production expectations are set at production of 2,000 bottles per day with a gradual increase to 8,000 bottles per day to fill demand. We already have over 50,000 bottles of full-spectrum distillate bottled and ready to ship with tens of thousands to follow.
We are also bottling a 250mg potency, which is perfect for the CBD-for-pets market. And, on the high end, we are also bottling 2500mg and 5000mg strengths, but we can replicate any formula.
Much of this production will be distributed under our proprietary brand, “Weed Got Oil”. But we are also actively pursuing a major place in the white label market for premium full-spectrum distillate CBD oil . There are over 400 brands now in the CBD space, and most of them turn to a major high-capacity producer, like HempAmericana, to build up an inventory of product.
For example, we recently announced a new relationship with Eagle Hemp of Florida (“Eagle Hemp”), located in the West Palm Beach area. This relationship now comprises an initial large purchase order and a clear path for a continuing series of purchase orders set to roll out over coming months and quarters.
The terms of the deal provide a window into the framework we have been working toward as we leverage our capital investments in our Augusta facility for the white label opportunity. We are set to receive strong demand at strong terms, including compensation for high-volume production of our premium CBD Oil output as well as our bottling technology.
In all, just in the first of these planned orders, we will receive a substantial revenue input, with no costs associated with bottling, labeling, or shipping of the final product.
Eagle Hemp is just one of many customers currently in play for our premium product output. The CBD market is turning out to be every bit the juggernaut that the major analyst firms have been suggesting over the past year. Estimates now range from several hundred to several thousand percentage points of gross sales expansion in the space over the next 36-48 months, which is a reasonable definition of boom conditions for a major industry in robust infancy.
The driver here, as we have elaborated in past communications, is about the seemingly bottomless demand growth function that accompanies the evolution of a product category from fringe consumer niche to mainstream adoption.
It is also important to note that we continue to receive requests from other industry customers and we are in the process of investigating the credibility of such requests and in negotiating similar terms for concrete relationships.
In addition, our production facility and lab are running along in amazing fashion. We now have two bottling machines active and operational due to the tremendous interest coming in the door. Once we have distilled this interest into official purchase orders, we will divulge them in our communications.
We also want to announce that our vaping machine is active and fully operational, we are now ready to produce and sell CBD vapes.
Finally, as we continue to expand, diversify, and integrate, we are now also working on plans to build a greenhouse dedicated to cultivating super-enriched seeds. We have always been committed to the long-term goal of fully controlling our production ecosystem from seed to product, and this is the next step in establishing that fully vertical model, where we see the strongest margins.
Best Regards,
Salvador Rosillo
As you can see, this is a company built for growth, and at just $0.007 per share, this could be one of the biggest steals in the entire cannabis sector.
Market Outlook for CBD:
New projections from the Brightfield Group in its June report suggest, if anything, a further acceleration in the overall growth of the CBD space, and some suggestion that this acceleration is being driven by an increasingly tangible jump in mainstream consumer adoption of CBD-based products. Specifically, the report notes that 2019 will show a 700% jump relative to 2018 levels for all domestic sales of CBD-based products, with 2019 on pace to exceed $5 billion in total sales of products containing CBD given current data. In addition, according to the Brightfield Group researchers, much of this jump will be due to sales in mainstream retail chain stores.
The cannabis market has grown at a tremendous pace over the recent years and as such, the industry has established itself a major global market. According to data compiled by Grand View Research, the global legal cannabis market is projected to reach USD 146.4 Billion by the 2025. It is also expected to grow at a CAGR of 34.6%. The market itself is witnessing a widespread legalization movement due to the growing adoption of the plant within the medical sector. Cannabis is being used heavily around the global for medical applications and treatments for maladies such as cancer, mental disorders, chronic pain, and others. However, the recreational market is thriving as well due specifically to the U.S. and Canada. States like California, Colorado, and Nevada are expected to propel the recreational sector forward at an encouraging rate.
The acceleration of research and development has led to new products within the market, enhancing consumer experiences. The research suggests that the industry is expecting strong exchanges of technological knowledge and information. Meanwhile, as countries like Canada, the U.S., Germany, and Australia lead the market in sales, countries like Israel are focusing on research and technology development to further expand within the industry. Additionally, there are various new forms of technology being introduced into the cannabis sector, such as virtual reality, payment solutions, and medical devices. "That's why we firmly believe that technology stands at the center of the industry's advancement and growth," said Ben Curren Chief Executive Officer of Green Bits, "This innovation will continue to generate market growth, improve public perception, protect public health and safety and enhance the implementation of state programs and regulations.
CBD is becoming widely accepted by consumers and countries. For example, in the U.S., CBD became legal after the Farm Bill that passed in late 2018.
That in mind, consumers could easily find CBD products across the U.S. In turn, we may actually see some CBD companies generating more revenues and earnings than cannabis companies.
Now, investment bank Cowen & Co. analysts estimate that the CBD market will reach $16B by 2025.
That said, CBD companies could experience exponential growth rates with such a large market. Not only that, large-cap drug stores like CVS and Walgreens have bet on CBD .
Additionally, CVS and Walgreens noted they would offer CBD products in more than 2,000 stores across the U.S.
Technical Analysis
Subpenny Stocks = Big Moves
We love these subpenny alerts because even the smallest move can result in massive gains for traders.
As we mentioned above, HMPQ is sitting on a bottom'd out chart with plenty of room to the upside.
We love these type of alerts because the downside risk appears minimal, but the upside is almost too good to ignore.
HMPQ is trading well off its 52-week of $0.0277.
A run back to those levels would net traders nearly +300% in profit from today's alert price.
We've done our very own chart analysis and see the potential for an explosive move in the very near future.
The Bottom-Line
We've been right on the money with our most recent cannabis sector alerts.
HMPQ is exactly the type of alert that we look for. Undervalued with major growth potential.
These are the types of alerts that offer traders the biggest payoff potential.
This could be our next subpenny alert to double in price, so make sure you have it on your radar!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated seventeen thousand five hundred dollars by One 22 Media LLC to conduct a one-day investor relations advertising and marketing campaign and 1,500 Trading View™ views for HMPQ. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Jul 29
Comment: CORRECTION
=====================
HempAmericana, Inc (HMPQ)
Alert Price: $0.007
========================
HMPQ is our new & exciting sub-penny CBD alert for tomorrow.
=====================
HempAmericana, Inc (HMPQ)
Alert Price: $0.0007
Website | Recent News
========================
Members,
We are coming off and incredible week of trading.
Last Thursday's alert broke out huge on on Friday, giving our members ample time to secure up to +76% in realistic profit.
This was our 4th winning trade alert in a row.
All in all, our members have had the opportunity to secure up to +225% in realistic profit in just about two weeks time.
We plan on keeping the good times rolling with a fresh trade idea that has the potential to double in price.
Please turn your immediate attention to HempAmericana, Inc (HMPQ).
Just like our most recent winners, HMPQ is sitting on a bottom'd out chart with plenty of room to the upside.
We've had a lot of success in the cannabis sector, our last pick in this space more than doubled in price in a very short amount of time.
HMPQ is quite enticing at the moment, as there are not many companies in the CBD sector trading for less than a penny.
And if there are, it is unlikely that they own and operate a high-capacity, state-of-the-art CBD extraction and processing facility like HMPQ does.
This is an exciting time for HMPQ shareholders, as the Company is witnessing quite the growth period.
Management recently updated shareholders on current inventory levels on hand for premium-quality CBD products. As of July 15, 2019, the Company holds CBD-based product inventories in excess of $500,000 based on current market pricing for end-market sales of comparable products. This inventory represents production over the past 60 days and includes CBD Extract, Crude CBD Oil , CBD Distillate, and bottled CBD Tincture.
Management believes it will improve margins over time as production smooths out and the volume absorbs fixed operating cost.
This is the kind of news we like to hear.
Wall St . loves nothing more than healthy margins and revenue growth.
It appears that we have found another gem in the CBD space with HMPQ.
We are urging all of our members to start their research on HMPQ immediately, and consider building a position tomorrow morning at 9:30AM EST.
About HempAmericana, Inc.
HempAmericana is an emerging participant in the CBD products market. The Company owns and operates a high-capacity, state-of-the-art CBD extraction and processing facility located in Augusta, Maine. This facility is armed with a supersized supercritical CO2 extraction system, centrifugal partition chromatography refinement technology, and a mechanized fully-automated CBD bottling system. The Company’s CBD oil business uses the brand designation, “Weed Got Oil”. HempAmericana also researches, develops, and sells products made of industrial hemp, including a popular brand of hemp rolling papers marketed under the brand name, “Rolling Thunders”. See more at http://www.hempamericana.com.
This Is An Exciting Time To Be A HMPQ Shareholder
In a recent corporate update CEO Salvador Rosillo painted a picture of a company gearing up for an amazing 2nd half of 2018.
Highlights Include:
A new relationship with Eagle Hemp of Florida (“Eagle Hemp”), located in the West Palm Beach area. This relationship now comprises an initial large purchase order and a clear path for a continuing series of purchase orders set to roll out over coming months and quarters.
Vaping machine is active and fully operational, they are now ready to produce and sell CBD vapes.
Plans to build a greenhouse dedicated to cultivating super-enriched seeds.
Improved margins
Please feel free to read the entire letter to shareholders below, we think you'll be just as impressed as we are.
Dear Valued Shareholder,
As we begin to establish growing momentum in our core CBD Oil production and distribution business, I wanted to take this opportunity to express our gratitude for your commitment and loyalty to our long-term value proposition and to discuss our current opportunities and our roadmap as we gear up to execute on the powerful opportunities that lie ahead.
As you know, we have commenced bottling 500mg and 1000mg full-spectrum CBD distillate in our state-of-the-art CBD extraction and production facility in Augusta, Maine. Our inaugural production expectations are set at production of 2,000 bottles per day with a gradual increase to 8,000 bottles per day to fill demand. We already have over 50,000 bottles of full-spectrum distillate bottled and ready to ship with tens of thousands to follow.
We are also bottling a 250mg potency, which is perfect for the CBD-for-pets market. And, on the high end, we are also bottling 2500mg and 5000mg strengths, but we can replicate any formula.
Much of this production will be distributed under our proprietary brand, “Weed Got Oil”. But we are also actively pursuing a major place in the white label market for premium full-spectrum distillate CBD oil . There are over 400 brands now in the CBD space, and most of them turn to a major high-capacity producer, like HempAmericana, to build up an inventory of product.
For example, we recently announced a new relationship with Eagle Hemp of Florida (“Eagle Hemp”), located in the West Palm Beach area. This relationship now comprises an initial large purchase order and a clear path for a continuing series of purchase orders set to roll out over coming months and quarters.
The terms of the deal provide a window into the framework we have been working toward as we leverage our capital investments in our Augusta facility for the white label opportunity. We are set to receive strong demand at strong terms, including compensation for high-volume production of our premium CBD Oil output as well as our bottling technology.
In all, just in the first of these planned orders, we will receive a substantial revenue input, with no costs associated with bottling, labeling, or shipping of the final product.
Eagle Hemp is just one of many customers currently in play for our premium product output. The CBD market is turning out to be every bit the juggernaut that the major analyst firms have been suggesting over the past year. Estimates now range from several hundred to several thousand percentage points of gross sales expansion in the space over the next 36-48 months, which is a reasonable definition of boom conditions for a major industry in robust infancy.
The driver here, as we have elaborated in past communications, is about the seemingly bottomless demand growth function that accompanies the evolution of a product category from fringe consumer niche to mainstream adoption.
It is also important to note that we continue to receive requests from other industry customers and we are in the process of investigating the credibility of such requests and in negotiating similar terms for concrete relationships.
In addition, our production facility and lab are running along in amazing fashion. We now have two bottling machines active and operational due to the tremendous interest coming in the door. Once we have distilled this interest into official purchase orders, we will divulge them in our communications.
We also want to announce that our vaping machine is active and fully operational, we are now ready to produce and sell CBD vapes.
Finally, as we continue to expand, diversify, and integrate, we are now also working on plans to build a greenhouse dedicated to cultivating super-enriched seeds. We have always been committed to the long-term goal of fully controlling our production ecosystem from seed to product, and this is the next step in establishing that fully vertical model, where we see the strongest margins.
Best Regards,
Salvador Rosillo
As you can see, this is a company built for growth, and at just $0.007 per share, this could be one of the biggest steals in the entire cannabis sector.
Market Outlook for CBD:
New projections from the Brightfield Group in its June report suggest, if anything, a further acceleration in the overall growth of the CBD space, and some suggestion that this acceleration is being driven by an increasingly tangible jump in mainstream consumer adoption of CBD-based products. Specifically, the report notes that 2019 will show a 700% jump relative to 2018 levels for all domestic sales of CBD-based products, with 2019 on pace to exceed $5 billion in total sales of products containing CBD given current data. In addition, according to the Brightfield Group researchers, much of this jump will be due to sales in mainstream retail chain stores.
The cannabis market has grown at a tremendous pace over the recent years and as such, the industry has established itself a major global market. According to data compiled by Grand View Research, the global legal cannabis market is projected to reach USD 146.4 Billion by the 2025. It is also expected to grow at a CAGR of 34.6%. The market itself is witnessing a widespread legalization movement due to the growing adoption of the plant within the medical sector. Cannabis is being used heavily around the global for medical applications and treatments for maladies such as cancer, mental disorders, chronic pain, and others. However, the recreational market is thriving as well due specifically to the U.S. and Canada. States like California, Colorado, and Nevada are expected to propel the recreational sector forward at an encouraging rate.
The acceleration of research and development has led to new products within the market, enhancing consumer experiences. The research suggests that the industry is expecting strong exchanges of technological knowledge and information. Meanwhile, as countries like Canada, the U.S., Germany, and Australia lead the market in sales, countries like Israel are focusing on research and technology development to further expand within the industry. Additionally, there are various new forms of technology being introduced into the cannabis sector, such as virtual reality, payment solutions, and medical devices. "That's why we firmly believe that technology stands at the center of the industry's advancement and growth," said Ben Curren Chief Executive Officer of Green Bits, "This innovation will continue to generate market growth, improve public perception, protect public health and safety and enhance the implementation of state programs and regulations.
CBD is becoming widely accepted by consumers and countries. For example, in the U.S., CBD became legal after the Farm Bill that passed in late 2018.
That in mind, consumers could easily find CBD products across the U.S. In turn, we may actually see some CBD companies generating more revenues and earnings than cannabis companies.
Now, investment bank Cowen & Co. analysts estimate that the CBD market will reach $16B by 2025.
That said, CBD companies could experience exponential growth rates with such a large market. Not only that, large-cap drug stores like CVS and Walgreens have bet on CBD .
Additionally, CVS and Walgreens noted they would offer CBD products in more than 2,000 stores across the U.S.
Technical Analysis
Subpenny Stocks = Big Moves
We love these subpenny alerts because even the smallest move can result in massive gains for traders.
As we mentioned above, HMPQ is sitting on a bottom'd out chart with plenty of room to the upside.
We love these type of alerts because the downside risk appears minimal, but the upside is almost too good to ignore.
HMPQ is trading well off its 52-week of $0.0277.
A run back to those levels would net traders nearly +300% in profit from today's alert price.
We've done our very own chart analysis and see the potential for an explosive move in the very near future.
The Bottom-Line
We've been right on the money with our most recent cannabis sector alerts.
HMPQ is exactly the type of alert that we look for. Undervalued with major growth potential.
These are the types of alerts that offer traders the biggest payoff potential.
This could be our next subpenny alert to double in price, so make sure you have it on your radar!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated seventeen thousand five hundred dollars by One 22 Media LLC to conduct a one-day investor relations advertising and marketing campaign and 1,500 Trading View™ views for HMPQ. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Jul 29
Comment: CORRECTION
=====================
HempAmericana, Inc (HMPQ)
Alert Price: $0.007
========================
CCCL Double Bottom FOUND Momentum With Bulls
China Ceramics Co., Ltd. is a manufacturer of ceramic tiles used for exterior siding and for interior flooring, and design in residential and commercial buildings. The Company's ceramic tiles, sold under the HD or Hengda, HDL or Hengdeli, Pottery Capital of Tang Dynasty, TOERTO and WULIQIAO brands, are available in over 2,000 styles, colors and size combinations. It operates in the segment of manufacturing and sale of medium to high-end ceramic tiles. Its geographical segment is People's Republic of China ( PRC ). It has five principal product categories: porcelain tiles, glazed tiles, glazed porcelain tiles, rustic tiles and polished glazed tiles. Its ceramic tiles are used for flooring, interior walls for decorative purposes and on exterior siding. The Company's manufacturing facilities are located in Jinjiang, Fujian Province and in Gaoan, Jiangxi Province. Combined, these facilities provide an aggregate annual production capacity of approximately 70 million square meters.
196. 17K 07/15/19 SHORT INTEREST
P/E Current
-0.06
P/E Ratio (with extraordinary items)
-0.08
CCCL Double Bottom FOUND Momentum With Bulls
China Ceramics Co., Ltd. is a manufacturer of ceramic tiles used for exterior siding and for interior flooring, and design in residential and commercial buildings. The Company's ceramic tiles, sold under the HD or Hengda, HDL or Hengdeli, Pottery Capital of Tang Dynasty, TOERTO and WULIQIAO brands, are available in over 2,000 styles, colors and size combinations. It operates in the segment of manufacturing and sale of medium to high-end ceramic tiles. Its geographical segment is People's Republic of China ( PRC ). It has five principal product categories: porcelain tiles, glazed tiles, glazed porcelain tiles, rustic tiles and polished glazed tiles. Its ceramic tiles are used for flooring, interior walls for decorative purposes and on exterior siding. The Company's manufacturing facilities are located in Jinjiang, Fujian Province and in Gaoan, Jiangxi Province. Combined, these facilities provide an aggregate annual production capacity of approximately 70 million square meters.
196. 17K 07/15/19 SHORT INTEREST
P/E Current
-0.06
P/E Ratio (with extraordinary items)
-0.08
WYY Bullish Divergence On Daily
WidePoint Corporation is a provider of information technology (IT)-based products, services and solutions. The Company offers secure, cloud-based, enterprise-wide IT-based solutions that enable commercial markets, and federal and state government organizations, to deploy fully compliant IT services in accordance with government-mandated regulations and advanced system requirements. The Company offers telecom management services, which include life cycle management of fixed and mobile assets; mobile security management services, which include life cycle fixed and mobile device access and application control management; identity management services, which include life cycle fixed and mobile, including cloud-based services authentication and information assurance services, and identity services, which include fixed and mobile digital certificates required for secure access to a customer's technology infrastructure.
SHORT INTEREST
17.59K 07/15/19
P/E Current
-24.54
P/E Ratio (with extraordinary items)
-58.95
Average Recommendation: BUY
Average Target Price: 1.00
WYY Bullish Divergence On Daily
WidePoint Corporation is a provider of information technology (IT)-based products, services and solutions. The Company offers secure, cloud-based, enterprise-wide IT-based solutions that enable commercial markets, and federal and state government organizations, to deploy fully compliant IT services in accordance with government-mandated regulations and advanced system requirements. The Company offers telecom management services, which include life cycle management of fixed and mobile assets; mobile security management services, which include life cycle fixed and mobile device access and application control management; identity management services, which include life cycle fixed and mobile, including cloud-based services authentication and information assurance services, and identity services, which include fixed and mobile digital certificates required for secure access to a customer's technology infrastructure.
SHORT INTEREST
17.59K 07/15/19
P/E Current
-24.54
P/E Ratio (with extraordinary items)
-58.95
Average Recommendation: BUY
Average Target Price: 1.00
OCUL - POSSIBLE 25% TREND MOVE ON THE DAILY
Ocular Therapeutix , Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
SHORT INTEREST
8.24M 07/15/19
P/E Current
-2.78
P/E Ratio (with extraordinary items)
-2.92
Average Recommendation: OVERWEIGHT
Average Target Price: 9.67
OCUL - POSSIBLE 25% TREND MOVE ON THE DAILY
Ocular Therapeutix , Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
SHORT INTEREST
8.24M 07/15/19
P/E Current
-2.78
P/E Ratio (with extraordinary items)
-2.92
Average Recommendation: OVERWEIGHT
Average Target Price: 9.67
LPTX - BREAK OUT - POSSIBLE 40% MOVE
Leap Therapeutics , Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .
Leap Therapeutics , Inc. ( LPTX ), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a conference call on August 6, 2019, to provide a program update for DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. (Source: https://finance.yahoo.com/news/leap-ther...)
SHORT INTEREST
2.1M 07/15/19
P/E Current
-0.95
P/E Ratio (with extraordinary items)
-1.34
Average Recommendation: BUY
Average Target Price: 9.00
LPTX - BREAK OUT - POSSIBLE 40% MOVE
Leap Therapeutics , Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .
Leap Therapeutics , Inc. ( LPTX ), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a conference call on August 6, 2019, to provide a program update for DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. (Source: https://finance.yahoo.com/news/leap-ther...)
SHORT INTEREST
2.1M 07/15/19
P/E Current
-0.95
P/E Ratio (with extraordinary items)
-1.34
Average Recommendation: BUY
Average Target Price: 9.00
SCON - Trending Nicely Momentum With Bulls
Superconductor Technologies , Inc. engages in the provision of high temperature superconducting materials and related technologies. Its products include Conductus superconducting wire, wireless solutions, and cryogenic solutions. The company was founded on May 11, 1987 and is headquartered in Austin, TX .
SHORT INTEREST
234.15K 07/15/19
P/E Current
-0.24
P/E Ratio (with extraordinary items)
-0.39
Average Recommendation: BUY
Average Target Price: 9.00
SCON - Trending Nicely Momentum With Bulls
Superconductor Technologies , Inc. engages in the provision of high temperature superconducting materials and related technologies. Its products include Conductus superconducting wire, wireless solutions, and cryogenic solutions. The company was founded on May 11, 1987 and is headquartered in Austin, TX .
SHORT INTEREST
234.15K 07/15/19
P/E Current
-0.24
P/E Ratio (with extraordinary items)
-0.39
Average Recommendation: BUY
Average Target Price: 9.00
ALPN - Starting To Clawback April Losses - Analyst's Bullish
Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.
15.61K 07/15/19 (Short Interest)
P/E Current
-1.52
P/E Ratio (with extraordinary items)
-1.63
Average Recommendation: BUY
Average Target Price: 13.50
ALPN - Starting To Clawback April Losses - Analyst's Bullish
Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. It optimizes native immune system proteins for use as therapeutics. The Company also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.
15.61K 07/15/19 (Short Interest)
P/E Current
-1.52
P/E Ratio (with extraordinary items)
-1.63
Average Recommendation: BUY
Average Target Price: 13.50
SUNW - Reversal Coming Due To Earnings In 7 Days?
Sunworks , Inc., formerly Solar3D , Inc., provides photo voltaic ( PV ) based power systems for the residential, commercial and agricultural markets in California and Nevada. The Company, through its operating subsidiaries, designs, arranges financing, integrates, installs and manages systems ranging in size from 2 kilowatt (KW) for residential loads to multi megawatts (MW) systems for larger commercial projects. The Company's commercial installations include office buildings, manufacturing plants, warehouses and agricultural facilities, such as farms, wineries and dairies. The Company provides a range of installation services to its solar energy customers, including design, system engineering, procurement, permitting, construction, grid connection, warranty, system monitoring and maintenance. The Company has installed over 850 systems in California and Nevada.
Sunworks , Inc. ( SUNW ), a premier provider of high-performance solar power solutions for agriculture, commercial, industrial ( ACI ), public works and residential markets, today announced it will report its second-quarter 2019 financial results prior to the market opening on Friday, August 2, 2019.
Management will host a conference call to discuss these results on the same day at 11 a.m. ET (8:00 a.m. PT). To access the call, please dial 1-844-602-0380 (toll free) or 1-862-298-0970 (international). The conference call will also be broadcast live over the Internet, which can be accessed via the Investor Relations section of Sunworks' web site at http://ir.sunworksusa.com. All participants should call or access the website approximately 5 minutes before the conference begins.
The webcast will be available for replay for at least 90 days. A telephonic replay of this conference call will also be available by dialing 1-919-882-2331 and using the replay ID #51702 until 11:00 a.m. ET on August 16, 2019.
(Source:https://finance.yahoo.com/news/sunworks-announce-second-quarter-2019-200200824.html?.tsrc=rss)
SHORT INTEREST
919.43K 07/15/19
P/E Current
-2.17
P/E Ratio (with extraordinary items)
-1.53
Average Recommendation: BUY
Average Target Price: 1.40
SUNW - Reversal Coming Due To Earnings In 7 Days?
Sunworks , Inc., formerly Solar3D , Inc., provides photo voltaic ( PV ) based power systems for the residential, commercial and agricultural markets in California and Nevada. The Company, through its operating subsidiaries, designs, arranges financing, integrates, installs and manages systems ranging in size from 2 kilowatt (KW) for residential loads to multi megawatts (MW) systems for larger commercial projects. The Company's commercial installations include office buildings, manufacturing plants, warehouses and agricultural facilities, such as farms, wineries and dairies. The Company provides a range of installation services to its solar energy customers, including design, system engineering, procurement, permitting, construction, grid connection, warranty, system monitoring and maintenance. The Company has installed over 850 systems in California and Nevada.
Sunworks , Inc. ( SUNW ), a premier provider of high-performance solar power solutions for agriculture, commercial, industrial ( ACI ), public works and residential markets, today announced it will report its second-quarter 2019 financial results prior to the market opening on Friday, August 2, 2019.
Management will host a conference call to discuss these results on the same day at 11 a.m. ET (8:00 a.m. PT). To access the call, please dial 1-844-602-0380 (toll free) or 1-862-298-0970 (international). The conference call will also be broadcast live over the Internet, which can be accessed via the Investor Relations section of Sunworks' web site at http://ir.sunworksusa.com. All participants should call or access the website approximately 5 minutes before the conference begins.
The webcast will be available for replay for at least 90 days. A telephonic replay of this conference call will also be available by dialing 1-919-882-2331 and using the replay ID #51702 until 11:00 a.m. ET on August 16, 2019.
(Source:https://finance.yahoo.com/news/sunworks-announce-second-quarter-2019-200200824.html?.tsrc=rss)
SHORT INTEREST
919.43K 07/15/19
P/E Current
-2.17
P/E Ratio (with extraordinary items)
-1.53
Average Recommendation: BUY
Average Target Price: 1.40
GNC - FIB Retracement - New Exclusive Product By MusclePharm
GNC Holdings, Inc. is a specialty retailer of health, wellness and performance products, which include protein, performance supplements, weight management supplements, vitamins, herbs and greens, wellness supplements, health and beauty, food and drink and other general merchandise. The Company's operations consist of purchasing raw materials, formulating and manufacturing products and selling the finished products. It operates in three segments: U.S. and Canada, International and Manufacturing/Wholesale. Its U.S. and Canada segment generates revenues primarily from sales of products to customers at its Company-owned stores in the United States, Canada and Puerto Rico , through its Websites, GNC .com and LuckyVitamin.com. Its International segment generates revenue primarily to its international franchisees. Its Manufacturing/Wholesale segment comprises its manufacturing operations in South Carolina and its wholesale partner relationships.
27.25M 07/15/19 (Short Interest)
P/E Ratio (with extraordinary items)
5.45
P/E Ratio (without extraordinary items)
2.93
Analyst Recommendation Price: $3.50
Analyst Recommendation: OVERWEIGHT
News: BURBANK, CA / ACCESSWIRE / July 25, 2019 / MusclePharm® Corporation (OTC PINK: MSLP) (“MusclePharm” or the “Company”), a scientifically driven, performance-lifestyle sports nutrition company, today announced the launch of eight ready to eat protein snacks with GNC , a leading health and wellness brand.
This launch includes MusclePharm’s long awaited and cutting-edge new protein snacking concept, Protein Candies, which will be sold exclusively at GNC . MusclePharm Protein Candies are single serving packs of multi-colored chocolate gems that provide 10g of protein, allowing consumers to indulge without the sacrifice. (Source: https://finance.yahoo.com/news/musclepha...)
GNC - FIB Retracement - New Exclusive Product By MusclePharm
GNC Holdings, Inc. is a specialty retailer of health, wellness and performance products, which include protein, performance supplements, weight management supplements, vitamins, herbs and greens, wellness supplements, health and beauty, food and drink and other general merchandise. The Company's operations consist of purchasing raw materials, formulating and manufacturing products and selling the finished products. It operates in three segments: U.S. and Canada, International and Manufacturing/Wholesale. Its U.S. and Canada segment generates revenues primarily from sales of products to customers at its Company-owned stores in the United States, Canada and Puerto Rico , through its Websites, GNC .com and LuckyVitamin.com. Its International segment generates revenue primarily to its international franchisees. Its Manufacturing/Wholesale segment comprises its manufacturing operations in South Carolina and its wholesale partner relationships.
27.25M 07/15/19 (Short Interest)
P/E Ratio (with extraordinary items)
5.45
P/E Ratio (without extraordinary items)
2.93
Analyst Recommendation Price: $3.50
Analyst Recommendation: OVERWEIGHT
News: BURBANK, CA / ACCESSWIRE / July 25, 2019 / MusclePharm® Corporation (OTC PINK: MSLP) (“MusclePharm” or the “Company”), a scientifically driven, performance-lifestyle sports nutrition company, today announced the launch of eight ready to eat protein snacks with GNC , a leading health and wellness brand.
This launch includes MusclePharm’s long awaited and cutting-edge new protein snacking concept, Protein Candies, which will be sold exclusively at GNC . MusclePharm Protein Candies are single serving packs of multi-colored chocolate gems that provide 10g of protein, allowing consumers to indulge without the sacrifice. (Source: https://finance.yahoo.com/news/musclepha...)
IAG - Strong Trend From Bottom - Good Supports Found
IAMGOLD Corp . engages in the exploration, development and production of gold and mineral resource properties. The company was founded by William D. Pugliese, Mark I. Nathanson, and Larry E. Phillips on March 27, 1990 and is headquartered in Toronto, Canada.
P/E Ratio (with extraordinary items)
-15.93
SHORT INTEREST
7.95M 07/15/19
Analyst Recommendation Target Price: 5.24
Analyst Recommendation: Overweight
IAG - Strong Trend From Bottom - Good Supports Found
IAMGOLD Corp . engages in the exploration, development and production of gold and mineral resource properties. The company was founded by William D. Pugliese, Mark I. Nathanson, and Larry E. Phillips on March 27, 1990 and is headquartered in Toronto, Canada.
P/E Ratio (with extraordinary items)
-15.93
SHORT INTEREST
7.95M 07/15/19
Analyst Recommendation Target Price: 5.24
Analyst Recommendation: Overweight
OAS - Had A Bad 2019 But Could Bounce BIG If Earnings Are GOOD
Oasis Petroleum Inc. is an independent exploration and production company. The Company is focused on the acquisition and development of unconventional oil and natural gas resources in the North Dakota and Montana regions of the Williston Basin. Its segments include Exploration and Production, Well Services, and Midstream Services. The exploration and production segment is engaged in the acquisition and development of oil and natural gas properties. The well services business segment (OWS) performs completion services for the Company's oil and natural gas wells operated by Oasis Petroleum North America LLC (OPNA). The midstream services business segment (OMS) performs salt water gathering and disposal services, fresh water services, natural gas gathering and processing and crude oil gathering and transportation and other midstream services for the Company's oil and natural gas wells operated by OPNA. The Company also operates a well services business and a midstream services business.
SHORT INTEREST
58.33M 07/15/19
P/E Ratio (with extraordinary items)
-9.78
Analyst Target Price: $7.06
Analyst Recommendations: OverWeight
Company Earnings Call 7 August.
OAS - Had A Bad 2019 But Could Bounce BIG If Earnings Are GOOD
Oasis Petroleum Inc. is an independent exploration and production company. The Company is focused on the acquisition and development of unconventional oil and natural gas resources in the North Dakota and Montana regions of the Williston Basin. Its segments include Exploration and Production, Well Services, and Midstream Services. The exploration and production segment is engaged in the acquisition and development of oil and natural gas properties. The well services business segment (OWS) performs completion services for the Company's oil and natural gas wells operated by Oasis Petroleum North America LLC (OPNA). The midstream services business segment (OMS) performs salt water gathering and disposal services, fresh water services, natural gas gathering and processing and crude oil gathering and transportation and other midstream services for the Company's oil and natural gas wells operated by OPNA. The Company also operates a well services business and a midstream services business.
SHORT INTEREST
58.33M 07/15/19
P/E Ratio (with extraordinary items)
-9.78
Analyst Target Price: $7.06
Analyst Recommendations: OverWeight
Company Earnings Call 7 August.
HMY - Still running With Strong Supports In Place
As of late, it has definitely been a great time to be an investor Harmony Gold Mining Company Limited HMY . The stock has moved higher by 82.6% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
We certainly think that this might be the case, particularly if you consider HMY’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as HMY has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company (Source: https://finance.yahoo.com/news/harmony-g...)
Harmony Gold Mining Company Limited, through its subsidiaries, is engaged in gold mining and related activities, including exploration, extraction and processing. The Company's segments include South Africa Underground, Surface, and International. The South Africa Underground segment includes Kusasalethu, Doornkop, Phakisa, Tshepong, Masimong, Target 1, Bambanani, Joel, Unisel and Target 3. The Surface segment comprises the Company's other surface operations. The Company's International segment comprises Hidden Valley Project. The Company has operations in South Africa and Papua New Guinea ( PNG ). The Company's principal product is the Gold bullion. The Company's exploration projects include Golpu project and Kili Teke prospect. The Company has approximately nine underground mines, one open pit operation and several surface sources in South Africa. The Company's subsidiaries include Lydenburg Exploration Limited, Tswelopele Beneficiation Operation (TBO) and Harmony Copper Limited.
SHORT INTEREST
6.8M 07/15/19
P/E Ratio (with extraordinary items)
-3.50
Analyst Recommendation: BUY
HMY - Still running With Strong Supports In Place
As of late, it has definitely been a great time to be an investor Harmony Gold Mining Company Limited HMY . The stock has moved higher by 82.6% in the past month, while it is also above its 20 Day SMA too. This combination of strong price performance and favorable technical, could suggest that the stock may be on the right path.
We certainly think that this might be the case, particularly if you consider HMY’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as HMY has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company (Source: https://finance.yahoo.com/news/harmony-g...)
Harmony Gold Mining Company Limited, through its subsidiaries, is engaged in gold mining and related activities, including exploration, extraction and processing. The Company's segments include South Africa Underground, Surface, and International. The South Africa Underground segment includes Kusasalethu, Doornkop, Phakisa, Tshepong, Masimong, Target 1, Bambanani, Joel, Unisel and Target 3. The Surface segment comprises the Company's other surface operations. The Company's International segment comprises Hidden Valley Project. The Company has operations in South Africa and Papua New Guinea ( PNG ). The Company's principal product is the Gold bullion. The Company's exploration projects include Golpu project and Kili Teke prospect. The Company has approximately nine underground mines, one open pit operation and several surface sources in South Africa. The Company's subsidiaries include Lydenburg Exploration Limited, Tswelopele Beneficiation Operation (TBO) and Harmony Copper Limited.
SHORT INTEREST
6.8M 07/15/19
P/E Ratio (with extraordinary items)
-3.50
Analyst Recommendation: BUY
JCP - Sephora Boosting Numbers for JCP
PARIS (Reuters) - U.S. sales at beauty retailer Sephora picked up in the second quarter after a sluggish end to 2018, its parent LVMH said on Wednesday, citing its continued tie-up with U.S. department store J.C. Penney.
The 117-year-old money-losing chain, based in Plano, Texas and which has rolled out hundreds of Sephora shops within its stores across the United States, hired advisers to explore debt restructuring options, Reuters reported last week.
J.C. Penney Co Inc said in a statement it had no significant near-term debt maturities and was not preparing for bankruptcy. (Sources: https://finance.yahoo.com/news/j-c-penne...)
J. C. Penney Company, Inc. is a holding company. The Company's business consists of selling merchandise and services to consumers through its department stores and its Website at jcpenney.com. Its department stores and Website generally serve the same type of customers, its Website offers virtually the same mix of merchandise as its store assortment and other categories, and its department stores generally accept returns from sales made in stores and through its Website. It fulfills online customer purchases by direct shipment to the customer from its distribution facilities and stores or from its suppliers' warehouses and by in store customer pick up. The Company sells family apparel and footwear, accessories, fine and fashion jewelry, beauty products through Sephora inside JCPenney, home furnishings and appliances. In addition, its department stores provide its customers with services, such as styling salon, optical, portrait photography and custom decorating.
121.87M 07/15/19 (Short Interest)
P/E Ratio (with extraordinary items)
-0.76
Analyst Price Prediction: $1.34
Recommendation: HOLD